References
- Konovalova S, Tyynismaa H. Mitochondrial aminoacyl-tRNA synthetases in human disease. Mol Genet Metab. 2013;108:206–211.
- Elo JM, Yadavalli SS, Euro L, et al. Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy. Hum Mol Genet. 2012;21:4521–4529.
- Shamseldin HE, Alshammari M, Al-Sheddi T, et al. Genomic analysis of mitochondrial diseases in a consanguineous population reveals novel candidate disease genes. J Med Genet. 2012;49:234–241.
- Almalki A, Alston CL, Parker A, et al. Chrzanowska-Lightowlers, Mutation of the human mitochondrial phenylalanine-tRNA synthetase causes infantile-onset epilepsy and cytochrome c oxidase deficiency. Biochim Biophys Acta. 2014;1842:56–64.
- Vernon HJ, McClellan R, Batista DA, et al. Mutations in FARS2 and non-fatal mitochondrial dysfunction in two siblings. Am J Med Genet. 2015;167A:1147–1151.
- de Kovel CG, Brilstra EH, van Kempen MJ, et al. Targeted sequencing of 351 candidate genes for epileptic encephalopathy in a large cohort of patients. Mol Genet Genomic Med. 2016;4:568–580.
- Raviglione F, Conte G, Ghezzi D, et al. Clinical findings in a patient with FARS2 mutations and early-infantile-encephalopathy with epilepsy. Am J Med Genet. 2016;170:3004–3007.
- Walker MA, Mohler KP, Hopkins KW, et al. Novel compound heterozygous mutations expand the recognized phenotypes of FARS2-linked disease. J Child Neurol. 2016;31:1127–1137.
- Yang Y, Liu W, Fang Z, et al. A newly identified missense mutation in FARS2 causes autosomal-recessive spastic paraplegia. Hum Mutat. 2016;37:165–169.
- Cho JS, Kim SH, Kim HY, et al. FARS2 mutation and epilepsy: Possible link with early-onset epileptic encephalopathy. Epilepsy Res. 2017;129:118–124.,
- Vantroys E, Larson A, Friederich M, et al. New insights into the phenotype of FARS2 deficiency. Mol Genet Metab. 2017;122:172–181.
- Almannai M, Wang J, Dai H, et al. FARS2 deficiency; new cases, review of clinical, biochemical, and molecular spectra, and variants interpretation based on structural, functional, and evolutionary significance. Mol Genet Metab. 2018;125:281–291.
- Sahai SK, Steiner RE, Au MG, et al. FARS2 mutations presenting with pure spastic paraplegia and lesions of the dentate nuclei. Ann Clin Transl Neurol. 2018;5:1128–1133.
- Rohl CA, Strauss CE, Misura KM, et al. Protein structure prediction using Rosetta. Methods Enzymol. 2004;383:66–93.
- Van Durme J, Delgado J, Stricher F, et al. A graphical interface for the FoldX forcefield. Bioinformatics. 2011;27:1711–1712.
- Andersen LW, Mackenhauer J, Roberts JC, et al. Etiology and therapeutic approach to elevated lactate levels. Mayo Clin Proc. 2013;88:1127–1140.
- Lipka K, Bulow HH. Lactic acidosis following convulsions. Acta Anaesthesiol Scand. 2003;47:616–618.
- Mendes A, Sampaio L. Brain magnetic resonance in status epilepticus: a focused review. Seizure. 2016;38:63–67.
- Cartagena AM, Young GB, Lee DH, et al. Reversible and irreversible cranial MRI findings associated with status epilepticus. Epilepsy Behav. 2014;33:24–30.,
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.